ArticleNature medicine2023
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 3 pooled it
19.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Performance of artificial intelligence for brain tumor segmentation, treatment planning, and outcome prediction: a comprehensive systematic review and meta-analysis.Journal of neuro-oncology · 2025Pooled it
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.Neuro-oncology · 2024Trial
- Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027Review
- A multidisciplinary program for meningioma treatment, research, and support services.Neuro-oncology practice · 2026Article
- Cell atlas of the developing human meninges reveals a dura-like nature of meningiomas.Nature cell biology · 2026Article
- FFPE-CUTAC: A Single Assay, Multiple Layers.bioRxiv : the preprint server for biology · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Risk stratification for meningiomas with discordant molecular classification.Acta neuropathologica · 2026Article
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- Spatially resolved single-cell analyses of human meningioma identify novel cell states influencing tumor microenvironment and progression.Nature genetics · 2026Article
- Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification.Journal of neuro-oncology · 2026Article
- Single-cell multi-omic techniques highlight the diverse composition and intercellular interactions of the vestibular schwannoma tumor microenvironment.Neuro-oncology advances · 2026Article
- STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.Nature communications · 2026Article
- A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.Nature genetics · 2026Article
- A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma.Neuro-oncology · 2026Article
- Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma.Acta neuropathologica communications · 2026Article
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
58 authors at 19 institutions in 6 countries.
William C ChenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. william.chen@ucsf.edu.ORCID 0000-0001-8924-5853
Abrar Choudhury *Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8312-2457
Mark W Youngblood *Department of Neurological Surgery, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-1044-8015
Mei-Yin C Polley *NRG Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA.
Calixto-Hope G LucasDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-8347-9592
Kanish MirchiaDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Sybren L N MaasDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Abigail K SuwalaDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Minhee WonNRG Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA.
James C BayleyJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.
Akdes S HarmanciDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Arif O HarmanciCenter for Secure Artificial Intelligence for Healthcare, Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX, USA.
Tiemo J KlischDepartment of Molecular and Human Genetics, Baylor College of Medicine, and Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0001-8182-384X
Minh P NguyenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Harish N VasudevanDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Kathleen McCortneyDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
Theresa J YuDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Varun BhaveDepartment of Neurosurgery, Brigham and Women's Hospital, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tai-Chung LamDepartment of Clinical Oncology, The University of Hong Kong, Pokfulam, China.
Jenny Kan-Suen PuDivision of Neurosurgery, Department of Surgery, The University of Hong Kong, Pokfulam, China.
Lai-Fung LiDivision of Neurosurgery, Department of Surgery, The University of Hong Kong, Pokfulam, China.
Gilberto Ka-Kit LeungDivision of Neurosurgery, Department of Surgery, The University of Hong Kong, Pokfulam, China.ORCID 0000-0003-3147-3057
Jason W ChanDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Haley K PerlowDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Joshua D PalmerDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.ORCID 0000-0003-3311-0129
Christine HaberlerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Anna S BerghoffDivision of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9379-6797
Matthias PreusserDivision of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3541-2315
Theodore P NicolaidesCaris Life Sciences, Phoenix, AZ, USA.
Christian MawrinDepartment of Neuropathology, University of Magdeburg, Magdeburg, Germany.
Sameer AgnihotriDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Adam ResnickDepartment of Neurological Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Brian R RoodBrain Tumor Institute, Children's National Hospital, Washington, DC, USA.
Jessica ChewDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Jacob S YoungDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Lauren BoretaDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Jessica SchulteNeurosciences Department, University of California San Diego, La Jolla, CA, USA.
Nicholas ButowskiDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Sandro SantagataDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7528-9668
David SpetzlerCaris Life Sciences, Phoenix, AZ, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
James P ChandlerDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.
David A SolomonDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4571-7999
C Leland RogersNRG Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA.
Stephanie L PughNRG Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA.
Minesh P MehtaNRG Statistics and Data Management Center, NRG Oncology, Philadelphia, PA, USA.
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Craig M HorbinskiDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA.ORCID 0000-0001-8340-9992
Michael W McDermottMiami Neuroscience Institute, Baptist Health, Miami, FL, USA.
Arie PerryDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8300-7261
Wenya Linda BiDepartment of Neurosurgery, Brigham and Women's Hospital, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Akash J PatelJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0001-5441-1962
Stephen T MagillDepartment of Neurological Surgery, Northwestern University, Chicago, IL, USA. stephen.magill@northwestern.edu.ORCID 0000-0002-5257-7835
David R RaleighDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. david.raleigh@ucsf.edu.ORCID 0000-0001-9299-8864
University of California, San Francisco · USNorthwestern University · USNRG Oncology · USUniversity of Hong Kong · HKBaylor College of Medicine · USBrigham and Women's Hospital · USMedical University of Vienna · ATBaptist Health South Florida · USCaris Life Sciences (United States) · USGerman Cancer Research Center · DENeurological Research Institute · USThe Ohio State University · USChildren's Hospital of Philadelphia · USChildren's National · USJohns Hopkins University · USLeiden University Medical Center · NLUniversity Hospital Magdeburg · DEUniversity of California San Diego · USUniversity of Pittsburgh · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Pouya Jamshidi · 2018 to 2026
$21.4MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MUnderstanding druggable drivers of meningioma tumorigenesisR01CA262311 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RALEIGH, DAVID R · 2021 to 2025
$2.7MUCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6MInvestigating the Regulation and Role of FOXM1 in Aggressive MeningiomaF30CA246808 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOUDHURY, ABRAR · 2020 to 2023
$159kDevelopment of a molecular diagnostic and prognostic signature for meningiomaF32CA213944 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAGILL, STEPHEN T · 2017 to 2017
$63kNCI NIH HHS F30 CA246808NCI NIH HHS F32 CA213944NCI NIH HHS K12 CA260225NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA221747NCI NIH HHS R01 CA262311NCI NIH HHS T32 CA151022NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NIGMS NIH HHS T32 GM007618
Abstract
Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and indications for postoperative radiotherapy are controversial. Here we develop a targeted gene expression biomarker that predicts meningioma outcomes and radiotherapy responses. Using a discovery cohort of 173 meningiomas, we developed a 34-gene expression risk score and performed clinical and analytical validation of this biomarker on independent meningiomas from 12 institutions across 3 continents (N = 1,856), including 103 meningiomas from a prospective clinical trial. The gene expression biomarker improved discrimination of outcomes compared with all other systems tested (N = 9) in the clinical validation cohort for local recurrence (5-year area under the curve (AUC) 0.81) and overall survival (5-year AUC 0.80). The increase in AUC compared with the standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval 0.07 to 0.17, P < 0.001). The gene expression biomarker identified meningiomas benefiting from postoperative radiotherapy (hazard ratio 0.54, 95% confidence interval 0.37 to 0.78, P = 0.0001) and suggested postoperative management could be refined for 29.8% of patients. In sum, our results identify a targeted gene expression biomarker that improves discrimination of meningioma outcomes, including prediction of postoperative radiotherapy responses.
Indexed as
Meningeal NeoplasmsMeningiomaBiomarkersGene Expression ProfilingHumansNeoplasm Recurrence, LocalProspective StudiesBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.